About FDA

Nicotine Steering Committee

“The FDA is envisioning a world where cigarettes can no longer create or sustain addiction, and where adults who still need or want nicotine can get it from alternative and less harmful sources.” Scott Gottlieb, M.D., October 19, 2017

Established September 2017, the FDA Nicotine Steering Committee (NSC) is a forum for developing and implementing nicotine policy and regulation. The Committee comprises senior leaders from the Center for Drug Evaluation and Research (CDER), the Center for Tobacco Products (CTP), and the Office of the Commissioner. The Committee ensures alignment of FDA’s centers and facilitates consensus and development of unified FDA positions on cross-cutting issues. The primary focus of the Committee is on the use of therapeutic nicotine for combustible tobacco product cessation.

For more information, please contact NSC@fda.hhs.gov.

Page Last Updated: 11/29/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English